Scienture (NASDAQ:SCNX) Stock Set to Reverse Split on Monday, October 5th

Scienture Holdings, Inc. (NASDAQ:SCNX) shares are going to reverse split on the morning of Monday, October 5th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Scienture Price Performance

SCNX stock traded down $0.08 during trading on Thursday, hitting $0.18. 1,900,908 shares of the stock traded hands, compared to its average volume of 2,214,886. The stock has a market cap of $7.27 million, a price-to-earnings ratio of -0.08 and a beta of 3.25. Scienture has a one year low of $0.18 and a one year high of $2.60. The company has a current ratio of 3.04, a quick ratio of 2.97 and a debt-to-equity ratio of 0.15. The company has a 50 day simple moving average of $0.37 and a 200 day simple moving average of $0.38.

Scienture (NASDAQ:SCNX) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $1.96 million.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Scienture has an average rating of “Hold” and a consensus target price of $1.50.

Institutional Trading of Scienture

A hedge fund recently bought a new stake in Scienture stock. Susquehanna International Group LLP bought a new stake in Scienture Holdings, Inc. (NASDAQ:SCNX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned 0.57% of Scienture at the end of the most recent quarter. 5.68% of the stock is owned by institutional investors and hedge funds.

About Scienture

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).